Condition

Irritable Bowel Syndrome

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 22 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials22

Recruiting3

Common interventions22

Lead sponsors shown15

Clinical trials

22 shown

Drug Interaction Potential of Pro-Inflammatory ConditionsNCT07360938 · 2025-11-01

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMANCT05754190 · 2023-06-20

Safety and Efficacy of Fecal Microbiota TransplantationNCT04014413 · 2019-07-15

Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and GLP1 Hormone in IBSNCT06408610 · 2024-05-01

Response of Irritable Bowel Syndrome to Abdominal Fat ReductionNCT05879692 · 2023-05-28

Early Signs of Parkinsons Disease in IBSNCT05573542 · 2023-05-01

ENROLLING_BY_INVITATION

Evaluation of the SIMBA Capsule for Small Intestinal DysbiosisNCT05633706 · 2023-01-09

ACTIVE_NOT_RECRUITING

Systems Biology of Gastrointestinal and Related DiseasesNCT05579444 · 2022-11-11

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component TrainingNCT05573685 · 2022-10-10

Neurocognitive Effects of FMT in MDD Patients With and Without IBSNCT05174273 · 2022-04-06

ACTIVE_NOT_RECRUITING

Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical ProblemsNCT02868983 · 2016-04-01

Genomic Resources for Enhancing Available Therapies (GREAT1.0) StudyNCT04306939 · 2014-11-01

Effects of Fasting on Self EfficacyNCT02113111 · 2014-04-01

25-hydroxyvitamin D and Fatigue: The VITALITY StudyNCT01718925 · 2012-10-01

Evaluating and Treating Potential Research Participants With Digestive DisordersNCT01736280 · 2012-09-17

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive DisorderNCT01337609 · 2011-06-01

Prognostic Indicators as Provided by the EPIC ClearViewNCT01476995 · 2010-09-01

MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic UseNCT01050465 · 2009-05-01

Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal PainNCT00824941 · 2009-02-06

Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major DepressionNCT01754493 · 2008-12-01

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice WorkflowNCT00634608 · 2008-02-01

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel SyndromeNCT00401258 · 2006-11-01

Common interventions

Leading sponsors

Cairo University 2 National Institute of Nursing Research (NINR) 2 University of Missouri-Columbia 2 Brown University 1 Chinese University of Hong Kong 1 Click Therapeutics, Inc. 1 Epic Research & Diagnostics, Inc. 1 Indiana University 1 Massachusetts General Hospital 1 Mclean Hospital 1 New York State Psychiatric Institute 1 Nimble Science Ltd. 1 Örebro University, Sweden 1 Ostfold Hospital Trust 1 Universität Duisburg-Essen 1

Trial status mix

COMPLETED9

TERMINATED4

RECRUITING3

ACTIVE_NOT_RECRUITING2

UNKNOWN2

ENROLLING_BY_INVITATION1

SUSPENDED1

Phase mix

NA8

PHASE43

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.